Charles River Laboratories International, Inc. (CRL): Shareholders' Equity
$3.17B
As of 2025-12-27
$2.85B
As of 2026-06-27
+2.1%
3-year compound annual growth
+8.4%
5-year compound annual growth
+15.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $3.17B | -8.6% | 2026-02-18, Balance as of period end |
| 2024-12-28 | $3.47B | -3.8% | 2026-02-18, Balance as of period end |
| 2023-12-30 | $3.60B | +20.8% | 2026-02-18, Balance as of period end |
| 2022-12-31 | $2.98B | +17.4% | 2025-02-19, Balance as of period end |
| 2021-12-25 | $2.54B | +19.9% | 2024-02-14, Balance as of period end |
| 2020-12-26 | $2.12B | +29.3% | 2023-02-22, Balance as of period end |
| 2019-12-28 | $1.64B | +24.1% | 2022-02-16, Balance as of period end |
| 2018-12-29 | $1.32B | +26.0% | 2021-02-17, Balance as of period end |
| 2017-12-30 | $1.05B | +24.8% | 2020-02-11, Balance as of period end |
| 2016-12-31 | $839.12M | +13.8% | 2019-02-13, Balance as of period end |
| 2015-12-26 | $737.56M | +9.1% | 2018-02-13, Balance as of period end |
| 2014-12-27 | $675.93M | +4.9% | 2017-02-14, Balance as of period end |
| 2013-12-28 | $644.08M | +6.8% | 2016-02-12, Balance as of period end |
| 2012-12-29 | $603.20M | +14.4% | 2015-02-17, Balance as of period end |
| 2011-12-31 | $527.36M | -23.4% | 2013-02-27, Balance as of period end |
| 2010-12-25 | $688.73M | -49.9% | 2013-02-27, Balance as of period end |
| 2009-12-26 | $1.37B | +10.6% | 2012-02-27, Balance as of period end |
| 2008-12-27 | $1.24B | n/a | 2011-02-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.17B | -8.6% |
| Incyte Corp (INCY) | 2025-12-31 | $5.17B | +49.9% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $459.07M | -44.4% |
| Icon PLC (ICLR) | 2025-12-31 | $9.19B | -2.6% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $6.63B | +9.3% |
| NRC Health (NRC) | 2025-12-31 | $13.99M | -55.3% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $171.49M | -16.9% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $267.03M | -7.2% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $11.14M | +109.3% |
Compare CRL, INCY, MEDP, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗